… The EGFR-TKIs investigated in this study were gefitinib and erlotinib. Afatinib had not yet
been approved by NHI during the study period. The prescription duration of individual EGFR-…

… erlotinib, we observed a poorer adjusted survival for gefitinib … , this study is the largest
European real-world cohort of … erlotinib, we observed a poorer adjusted survival for gefitinib …

… As mentioned above, both randomized controlled trials and cohort studies were included in
… bias in cohort studies, with emphasis on comparability between gefitinib and erlotinib groups …

… Gefitinib and erlotinib are tyrosine kinase inhibitors (TKIs) specific for the epidermal growth
factor receptor (EGFR). The response rate to TKIs was significantly high in NSCLC patients of …

… every 21 days), or gefitinib (250 mg orally daily). Erlotinib and gefitinib were given to patients
… the start of treatment with the study drug (docetaxel, erlotinib, or gefitinib). Response was …

… A retrospective cohort study of 88 NSCLC patients with EGFR mutation positive treated
with gefitinib (n=59), erlotinib (n=22), and afatinib (n=7) was performed in national cancer …

… This retrospective cohort study was conducted using data from real-world settings. Patients
with stage IIIB and IV NSCLC and first received gefitinib, erlotinib, or afatinib between 2011 …

… Such an uneven distribution of squamous cell carcinoma may interfere with the observation
of the efficacy of erlotinib in the entire study cohort. However, no differences in OS or TTF …

… -based cohort study demonstrated that concurrent PPI with gefitinib or erlotinib was
associated with significantly poorer OS and TTNT than the H2RA and non-user. Other studies …

… incidence of ILD in the current cohort study (Table 3). A previous Japanese study also
showed a higher incidence of ILD emergence during gefitinib therapy in patients with a poor PS (…